# A Study of LOR-253 HCl in Patients With Advanced or Metastatic Solid Tumours

> **NCT01281592** · PHASE1 · COMPLETED · sponsor: **Aptose Biosciences Inc.** · enrollment: 36 (actual)

## Conditions studied

- Advanced or Metastatic Solid Tumours

## Interventions

- **DRUG:** LOR-253 HCl

## Key facts

- **NCT ID:** NCT01281592
- **Lead sponsor:** Aptose Biosciences Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2013-07
- **Final completion:** 2014-01
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2014-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01281592

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01281592, "A Study of LOR-253 HCl in Patients With Advanced or Metastatic Solid Tumours". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01281592. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*